WO2020111167A1 - Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 - Google Patents

Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 Download PDF

Info

Publication number
WO2020111167A1
WO2020111167A1 PCT/JP2019/046505 JP2019046505W WO2020111167A1 WO 2020111167 A1 WO2020111167 A1 WO 2020111167A1 JP 2019046505 W JP2019046505 W JP 2019046505W WO 2020111167 A1 WO2020111167 A1 WO 2020111167A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
amino acid
phb2
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2019/046505
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
豊雅 片桐
哲郎 吉丸
章 大高
宮本 貴史
康秀 岡本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Tokushima University
Original Assignee
Oncotherapy Science Inc
Tokushima University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc, Tokushima University filed Critical Oncotherapy Science Inc
Priority to EP19890179.5A priority Critical patent/EP3889264A4/en
Priority to US17/297,986 priority patent/US12595289B2/en
Priority to JP2020557810A priority patent/JP7525855B2/ja
Publication of WO2020111167A1 publication Critical patent/WO2020111167A1/ja
Anticipated expiration legal-status Critical
Priority to JP2024005446A priority patent/JP7726464B2/ja
Priority to US19/546,792 priority patent/US20260234205A1/en
Priority to US19/546,921 priority patent/US20260209292A1/en
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the estrogen receptor (ER) activation regulatory molecule BIG3 interacts with the inhibitor PHB2 to induce constitutive activation of ER, and the BIG3-PHB2 interaction target inhibitor peptide (ERAP: BIG3 protein).
  • the estrogen (E2)-dependent breast cancer cell growth inhibitory effect by the amino acid sequence from 165th position to 177th position has been clarified (Patent Document 1, WO2017/126461).
  • ERAP acts as an inhibitor of interaction by binding to PHB2, but PHB2 is expressed in human whole body organs, thus denying expression of non-selective effects in organs other than cancer tissues. I can't.
  • the present inventors have found a PHB2-derived peptide that inhibits the BIG3-PHB2 interaction and exerts an antitumor effect against E2-dependent breast cancer and triple negative breast cancer, and completed the present invention. That is, the present invention provides the following peptides and their uses.
  • FIG. 3 shows a schematic diagram of branched and cyclic PHB2 peptides.
  • A Linear bond type PHB2 peptide.
  • B Branched PHB2 peptide.
  • C Cyclic PHB2 peptide.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/JP2019/046505 2018-11-30 2019-11-28 Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 Ceased WO2020111167A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP19890179.5A EP3889264A4 (en) 2018-11-30 2019-11-28 BREAST CANCER THERAPEUTIC WITH BIG3-PHB2 INTERACTION INHIBITING PEPTIDE FROM PHB2
US17/297,986 US12595289B2 (en) 2018-11-30 2019-11-28 Therapeutic agent for breast cancer comprising BIG3-PHB2 interaction-inhibiting peptide derived from PHB2
JP2020557810A JP7525855B2 (ja) 2018-11-30 2019-11-28 Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬
JP2024005446A JP7726464B2 (ja) 2018-11-30 2024-01-17 Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬
US19/546,792 US20260234205A1 (en) 2018-11-30 2026-02-23 Therapeutic agent for breast cancer comprising big3-phb2 interaction-inhibiting peptide derived from phb2
US19/546,921 US20260209292A1 (en) 2018-11-30 2026-02-23 Therapeutic agent for breast cancer comprising big3-phb2 interaction-inhibiting peptide derived from phb2

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018225660 2018-11-30
JP2018-225660 2018-11-30

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US17/297,986 A-371-Of-International US12595289B2 (en) 2018-11-30 2019-11-28 Therapeutic agent for breast cancer comprising BIG3-PHB2 interaction-inhibiting peptide derived from PHB2
US19/546,792 Continuation US20260234205A1 (en) 2018-11-30 2026-02-23 Therapeutic agent for breast cancer comprising big3-phb2 interaction-inhibiting peptide derived from phb2
US19/546,921 Continuation US20260209292A1 (en) 2018-11-30 2026-02-23 Therapeutic agent for breast cancer comprising big3-phb2 interaction-inhibiting peptide derived from phb2

Publications (1)

Publication Number Publication Date
WO2020111167A1 true WO2020111167A1 (ja) 2020-06-04

Family

ID=70853835

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/046505 Ceased WO2020111167A1 (ja) 2018-11-30 2019-11-28 Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬

Country Status (4)

Country Link
US (3) US12595289B2 (cg-RX-API-DMAC7.html)
EP (1) EP3889264A4 (cg-RX-API-DMAC7.html)
JP (2) JP7525855B2 (cg-RX-API-DMAC7.html)
WO (1) WO2020111167A1 (cg-RX-API-DMAC7.html)

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722858A (en) 1985-07-01 1988-02-02 Du Pont Canada Inc. Fire-retardant sheet material
US5580895A (en) 1992-01-21 1996-12-03 Glaxo Spa 1,5-benzodiazepine derivatives
US5589466A (en) 1989-03-21 1996-12-31 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
WO1997016171A1 (fr) 1995-11-01 1997-05-09 Dnavec Research Inc. Liposome a membrane fusible faisant appel a un virus sendai recombinant
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
WO1998004720A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
WO1999067288A1 (en) 1998-06-25 1999-12-29 Sumitomo Pharmaceuticals Company, Limited Tumor antigen peptides originating in cyclophilin b
WO2013018690A1 (ja) * 2011-07-29 2013-02-07 国立大学法人徳島大学 Erap1由来ペプチド及びその使用
WO2017126461A1 (ja) 2016-01-19 2017-07-27 国立大学法人徳島大学 がん治療用ペプチド及びそれを含む医薬組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7998695B2 (en) 2005-02-10 2011-08-16 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
JP5339291B2 (ja) 2006-08-10 2013-11-13 オンコセラピー・サイエンス株式会社 乳癌に関連する遺伝子およびポリペプチド
CN111148752B (zh) 2017-07-19 2024-01-16 国立大学法人德岛大学 肽衍生物和包含其的药物组合物

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722858A (en) 1985-07-01 1988-02-02 Du Pont Canada Inc. Fire-retardant sheet material
US5589466A (en) 1989-03-21 1996-12-31 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5580895A (en) 1992-01-21 1996-12-03 Glaxo Spa 1,5-benzodiazepine derivatives
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
WO1997016171A1 (fr) 1995-11-01 1997-05-09 Dnavec Research Inc. Liposome a membrane fusible faisant appel a un virus sendai recombinant
WO1998004720A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
WO1999067288A1 (en) 1998-06-25 1999-12-29 Sumitomo Pharmaceuticals Company, Limited Tumor antigen peptides originating in cyclophilin b
WO2013018690A1 (ja) * 2011-07-29 2013-02-07 国立大学法人徳島大学 Erap1由来ペプチド及びその使用
WO2017126461A1 (ja) 2016-01-19 2017-07-27 国立大学法人徳島大学 がん治療用ペプチド及びそれを含む医薬組成物

Non-Patent Citations (61)

* Cited by examiner, † Cited by third party
Title
"Basics and Experiment of Peptide Synthesis", 1985, MARUZEN CO.
"GenBank", Database accession no. NM_001267700.1
"Peptide Synthesis", 1975, INTERSCIENCE
"peptide synthesis", vol. 14, 1991, article "Development of Pharmaceuticals"
"The Proteins", vol. 2, 1976, ACADEMIC PRESS
BARANY G.MERRIFIELD R.B.: "Solid Phase Peptide Synthesis", vol. 2, 1980, ACADEMIC PRESS, article "Peptides", pages: 100 - 118
BEAUCAGE SLIYER RP, TETRAHEDRON, vol. 48, 1992, pages 2223 - 311
BETTER ET AL., SCIENCE, vol. 240, no. 4855, 1988, pages 1041 - 3
CHLEBOWSKI, R. ET AL., BREAST, vol. 2, 2009, pages 1 - 11
CHUMSRI, S. ET AL., J. STEROID BIOCHEM. MOL. BIOL., vol. 125, no. 1-2, 2011, pages 13 - 22
CLARK-CURTISSCURTISS ET AL.: "Methods in Enzymology", vol. 101, 1983, pages: 347 - 62
CLARKE, R. ET AL., PHARMACOL. REV., vol. 53, no. 1, 2001, pages 25 - 71
COOS VERHOEF ET AL., EUR. J. DRUG METAB. PHARMACOKIN., vol. 11, no. 4, 1986, pages 291 - 302
CREIGHTON, PROTEINS, 1984
DALBADIE-MCFARLAND ET AL., PROC NATL ACAD SCI USA, vol. 79, no. 21, 1982, pages 6409 - 13
DEROSSI ET AL., J. BIOL. CHEM., vol. 269, no. 14, 1994, pages 10444 - 50
ELMQUIST ET AL., EXP. CELL RES., vol. 269, no. 2, 2001, pages 237 - 44
FASEB J, vol. 6, no. 7, 1992, pages 2422 - 7
FISHER, B. ET AL., J. NATL. CANCER INST., vol. 93, no. 9, 2001, pages 684 - 90
FISHER, B. ET AL., J. NATL. CANCER INST., vol. 97, no. 22, 2005, pages 1652 - 62
GAO ET AL., BIOORG. MED. CHEM., vol. 10, no. 12, 2002, pages 4057 - 65
GREENLOEWENSTEIN, CELL, vol. 55, no. 6, 1988, pages 1179 - 88
HIPP ET AL., IN VIVO, vol. 14, no. 5, 2000, pages 571 - 85
HONGCLAYMAN, CANCER RES., vol. 60, no. 23, 2000, pages 6551 - 6
HOPP ET AL., BIO/TECHNOLOGY, vol. 6, 1988, pages 1204 - 10
JOHNSTON, S. R., CLIN. CANCER RES., vol. 16, no. 7, 2010, pages 1979 - 87
JOLIOT A.PROCHIANTZ A., NAT CELL BIOL., vol. 6, 2004, pages 189 - 96
JORDAN, V. C., NATURE REV. DRUG DISCOV., vol. 2, no. 3, 2003, pages 205 - 13
KASASHIMA K, J BIOL CHEM, vol. 281, no. 47, 2006, pages 36401 - 10
KIM JWAKIYAMA MPARK JH ET AL., CANCER SCI., vol. 100, no. 8, 2009, pages 1468 - 78
LEI ET AL., J BACTERIOL, vol. 169, no. 9, 1987, pages 4379 - 83
LIN ET AL., J. BIOL. CHEM., vol. 270, no. 24, 1995, pages 14255 - 8
LUNDBERG ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 299, no. 1, 2002, pages 85 - 90
MARK ET AL., PROC NATL ACAD SCI USA, vol. 81, no. 18, 1984, pages 5662 - 6
MARQUEZ-GARBAN DC ET AL., STEROIDS, vol. 72, no. 2, 2007, pages 135 - 43
MATSUSHITA ET AL., J. NEUROSCI., vol. 21, no. 16, 2003, pages 6000 - 7
MATTHES ET AL., EMBO J, vol. 3, no. 4, 1984, pages 801 - 5
MIZUSHIMA ET AL., NUCLEIC ACIDS RES, vol. 18, no. 17, 1990, pages 5322
MONTANO MM ET AL., PROC NATL ACAD SCI USA., vol. 96, no. 12, 1999, pages 6947 - 52
MORRIS ET AL., NATURE BIOTECHNOL., vol. 19, no. 2, 2001, pages 1173 - 6
MORRISON J, J BACTERIOLOGY, vol. 132, no. 1, 1977, pages 349 - 51
MULLIGAN ET AL., NATURE, vol. 277, no. 5692, 1979, pages 108 - 14
NELLES JL ET AL., EXPERT REV ENDOCRINOL METAB., vol. 6, no. 3, 2011, pages 437 - 51
OEHLKE ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 1414, no. 1-2, 1998, pages 127 - 39
PARK ET AL., PROC. NATL ACAD. SCI. USA, vol. 97, no. 15, 2000, pages 8245 - 50
POOGA ET AL., FASEB J., vol. 12, no. 1, 1998, pages 67 - 77
ROUSSELLE ET AL., MOL. PHARMACOL., vol. 57, no. 4, 2000, pages 679 - 86
SAWADA ET AL., NATURE CELL BIOL., vol. 5, no. 4, 2003, pages 352 - 7
SHATA ET AL., MOL MED TODAY, vol. 6, no. 2, 2000, pages 66 - 71
SHEDLOCK ET AL., J LEUKOC BIOL, vol. 68, no. 6, 2000, pages 793 - 806
STABILE LP ET AL., CANCER RES., vol. 65, no. 4, 2005, pages 1459 - 70
STOVER ET AL., NATURE, vol. 351, no. 6326, 1991, pages 456 - 60
THOMAS KRCAPECCHI MR, CELL, vol. 51, no. 3, 1987, pages 503 - 12
WARD ET AL., NATURE, vol. 341, no. 6242, 1989, pages 544 - 6
WOLFF ET AL., SCIENCE, vol. 247, 1990, pages 1465 - 8
YI-AN CHEN;YOICHI MURAKAMI;SHANDAR AHMAD;TETSURO YOSHIMARU;TOYOMASA KATAGIRI;KENJI MIZUGUCHI: "Brefeldin A-inhibited guanine nucleotide-exchange protein 3(BIG3) is predicted to interact with its partner through an ARM-type a-helical structure", BMC RESEARCH NOTES, vol. 7, 435, 6 July 2014 (2014-07-06), pages 1 - 8, XP021191174, ISSN: 1756-0500, DOI: 10.1186/1756-0500-7-435 *
YOSHIMARU TETSURO : "2P-0632: A-kinase anchoring protein BIG3-PHB2axis is required for progression of HER2-rich breastcancer cells", 41ST ANNUAL MEETING OF THE MOLECULAR BIOLOGY SOCIETY OF JAPAN; NOVEMBER 28-30, 2018, vol. 41, 9 November 2018 (2018-11-09), JP, XP009528043 *
YOSHIMARU, T. ET AL., NAT. COMMUN., vol. 4, 2013, pages 2443
YOSHIMARU, T. ET AL., SCI REP., vol. 7, no. 1, 2017, pages 1821
YUBA E ET AL., J. CONTROL. RELEASE, vol. 149, 2011, pages 72 - 80
ZOLLERSMITH, NUCLEIC ACIDS RES, vol. 10, no. 20, 1982, pages 6487 - 500

Also Published As

Publication number Publication date
US20220098256A1 (en) 2022-03-31
JP7726464B2 (ja) 2025-08-20
JP7525855B2 (ja) 2024-07-31
US20260209292A1 (en) 2026-07-23
US12595289B2 (en) 2026-04-07
EP3889264A1 (en) 2021-10-06
JPWO2020111167A1 (ja) 2021-10-28
JP2024045244A (ja) 2024-04-02
EP3889264A4 (en) 2022-10-12
US20260234205A1 (en) 2026-08-13

Similar Documents

Publication Publication Date Title
US11884708B2 (en) Stapled peptide inhibitors of nemo as potential anti-inflammatory and anti-cancer drugs
JP6014904B2 (ja) Erap1由来ペプチド及びその使用
US10087215B2 (en) Stabilized SOS1 peptides
WO2004092339A2 (en) Modulation of muc1 mediated signal transduction
EP3066113A2 (en) Peptide inhibitors of tead/yap-taz interaction
AU2022203604A1 (en) COMPOSITIONS, ASSAYS, AND METHODS FOR TARGETING HDM2 AND HDMX TO REVERSE THE INHIBITION OF p53 IN PEDIATRIC CANCERS
IL275774A (en) Variants of ATF5 peptide and their uses
US10106590B2 (en) BH4 stabilized peptides and uses thereof
CN101146822A (zh) EphB受体结合肽
JP2024028553A (ja) Dpep-1結合剤および使用の方法
WO2014142619A1 (ko) Aimp2-dx2와 pl4/arf의 상호작용을 이용한 암 치료제의 스크리닝 방법
CN115397513A (zh) 改进的抗衰老化合物及其用途
IL295634A (en) Molecules targeting ras protein
JP7525855B2 (ja) Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬
US10907212B2 (en) Inhibitors of cell adhesion
Crnković-Mertens et al. Isolation of peptides blocking the function of anti-apoptotic Livin protein
CN111148752A (zh) 肽衍生物和包含其的药物组合物
US12552834B2 (en) Selective MENA binding peptides
Hansen et al. Identification of Amino Acid Residues in PEPHC1 Important for Binding to the Tumor‐Specific Receptor EGFRvIII
EP2392585A2 (en) Scaffold proteins for recombinant peptide aptamers
KR20250138134A (ko) 표적 단백질 분해자 및 세포 투과 펩타이드를 포함하는 융합 분자 및 이의 용도
Afrose Influence of Single and Multiple Histidine Residues and Their Ionization Properties on Transmembrane Helix Dynamics, Orientations and Fraying
Wen Development and Application of Cell Penetrating Beta-Hairpin and Alpha-Helical Peptides
Quach Investigating the Factors that Affect Trafficking of Hydrocarbon-Stapled Peptides and the Epidermal Growth Factor Receptor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19890179

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020557810

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019890179

Country of ref document: EP

Effective date: 20210630

WWG Wipo information: grant in national office

Ref document number: 17297986

Country of ref document: US